Source comparison
BPC-157 LL-37 Stack: Clinical Application Comparison
Primary Mechanism VEGF-mediated angiogenesis, collagen synthesis, NO pathway activation Direct antimicrobial membrane disruption, neutrophil chemotaxis, biofilm degradation Dual-pathway: tissue regeneration + pathogen clearance Combined stack addresses both in
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF-mediated angiogenesis, collagen synthesis, NO pathway activation
- Direct antimicrobial membrane disruption, neutrophil chemotaxis, biofilm degradation
- Dual-pathway: tissue regeneration + pathogen clearance
- Combined stack addresses both infection and tissue damage. Monotherapy leaves one pathway unaddressed
- Typical Dosing
- 250–500 mcg daily SC
- 2–5 mg 3×/week SC
- Both peptides at standard doses
- Dosing remains independent. No need to reduce either peptide when stacking
- Observable Effect Timeline
- 3–4 weeks for wound size reduction
- 7–10 days for reduced microbial load
- 2–3 weeks for combined antimicrobial + tissue healing
- Stack shows earlier observable improvements than BPC-157 alone, more sustained than LL-37 alone
- Biofilm Penetration
- Minimal. Primarily improves vascular access
- High. Disrupts biofilm matrix at 10–50 μg/mL
- High. LL-37 disrupts biofilm, BPC-157 rebuilds underlying tissue
- Critical for chronic infections where biofilms shield bacteria from immune clearance
- Systemic vs Local Effect
- Systemic distribution through lymphatic circulation
- Local antimicrobial effect + systemic immune modulation
- Combined systemic + local effects
- Injection proximity to infection site enhances both peptides' local concentration
- Professional Assessment
- Best for non-infected tissue damage or post-infection tissue repair
- Best for acute infection with intact tissue structure
- Optimal for chronic infections with concurrent tissue compromise. Addresses both pathogen burden and healing deficit